Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

“Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world.”

"In the New Health, biopharmaceutical companies are under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines to patients in need," said Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories. "Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world."

Under the non-exclusive alliance, Quintiles and London Genetics will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, Quintiles and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.

"Our expertise in pharmacogenetic strategy development combined with Quintiles' expertise and infrastructure in biomarker development gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development," said Dominique Kleyn, CEO of London Genetics. "Ultimately, our alliance will support biopharma in their interactions with academic partners and the development of personalized medicines."